Beyondspring

Beyondspring Cash Conversion Cycle

The Cash Conversion Cycle (CCC) of Beyondspring (BYSI) as of Oct 10, 2026 is -1,522.93. In the previous year, Cash Conversion Cycle (CCC) was -377.81 — a change of 303.10% (lower).

Cash Conversion Cycle

-1,522.93

YoY

303.10%

Last updated:

Cash Conversion Cycle (CCC) of Beyondspring is 2025 -1,522.93 . Cash Conversion Cycle (CCC) of Beyondspring was 2024 -377.81 . It decreases by 303.10% lower compared to the previous year.

The Beyondspring Cash Conversion Cycle history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

Cash Conversion Cycle
Date
Cash Conversion Cycle
Jan 1, 2016
7,198.61 USD
Jan 1, 2017
-38,541.72 USD
Jan 1, 2018
-63,700.10 USD
Jan 1, 2019
-12,026.04 USD
Jan 1, 2020
-10,504.42 USD
Jan 1, 2023
-678.03 USD
Jan 1, 2024
-377.81 USD
Jan 1, 2025
-1,522.93 USD
The Beyondspring Cash Conversion Cycle history
YEARCash Conversion CycleYoY
-1,522.93+303.10%
-377.81-44.28%
-678.03-93.55%
-10,504.42-12.65%
-12,026.04-81.12%
-63,700.10+65.28%
-38,541.72-635.40%
7,198.61-193.47%
-7,701.50—
Access this data via the Eulerpool API

Beyondspring Stock analysis

What does Beyondspring do? Beyondspring Inc is a globally operating biopharmaceutical company dedicated to the development of innovative cancer drugs. The company was founded in 2014 in New York City and today Beyondspring is based in New York and Shanghai. The founding of Beyondspring aimed to bring innovative cancer therapies to market that provide better treatment outcomes for patients. The company particularly focuses on a combination of proven therapeutic approaches and innovative technology, aiming to take a leading role in the oncology industry. Beyondspring focuses on the development of highly effective cancer therapies based on two platform technologies: protein engineering and immuno-oncology. The company is searching for substances that can strengthen the body's immune system and attack cancer cells. At the core of its business operations is the product Plinabulin. This is a novel cyclic peptide drug that is capable of activating the immune system and destroying cancer cells. The drug has been tested in multiple clinical trials and has shown promising results, particularly in breast cancer and lung cancer. In addition to product development, Beyondspring is also involved in the market development and commercialization of cancer drugs. The company works closely with hospitals, doctors, and other healthcare stakeholders to promote the use of Plinabulin and improve patient care. Beyondspring specializes in various types of cancer, such as lung cancer, breast cancer, and leukemia, where Plinabulin can be used. The company strives to constantly expand its product portfolio to explore additional indications. Beyondspring's business model relies on close collaboration with industry partners and the establishment of a global network. The company collaborates with leading research institutions and universities and continuously invests in the development of innovative technologies. The goal of Beyondspring is to provide cancer patients worldwide with access to innovative and highly effective treatment options. To achieve this, the company collaborates with regulatory authorities to expedite the approval of new drugs. Overall, Beyondspring is characterized by a highly dynamic and future-oriented business model. With its focus on innovative cancer therapies and the continuous expansion of its portfolio, the company has already established a strong position in the industry. In the future, Beyondspring will continue to expand its global presence and broaden its product range to provide cancer patients with the best possible treatment outcomes. Beyondspring is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Beyondspring stock

Cash Conversion Cycle (CCC) of Beyondspring is -1,522.93 in 2025.

Cash Conversion Cycle (CCC) of Beyondspring changed from -377.81 to -1,522.93, representing a 303.10% change. The value is lower than the previous year.

On Eulerpool you can find the complete historical development of Cash Conversion Cycle (CCC) Beyondspring since 2006 – with annual values, charts, and detailed analysis.

The Cash Conversion Cycle measures how long it takes to convert inventory investments into cash from sales. A shorter CCC indicates more efficient working capital management.

CCC = DSO + DIO - DPO

A 'good' varies by industry and company stage. On Eulerpool, you can compare Cash Conversion Cycle (CCC)'s Beyondspring with sector peers and the industry average to assess whether it is attractive.

To evaluate Cash Conversion Cycle (CCC)'s, it is essential to compare it with peers in the same industry and sector. On Eulerpool, you can find direct industry comparisons for Cash Conversion Cycle (CCC).

Access this data via the Eulerpool API

Profitability — Beyondspring

All Key Metrics — Beyondspring